We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The current VYGR market cap is 313.55M. The company's latest EPS is USD 2.4225 and P/E is 2.37.
Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 4.61M | 90.06M | 19.52M | 29.58M | 24.63M |
Operating Income | -29.51M | 54.06M | -16.18M | -15.03M | -13.78M |
Net Income | -25.9M | 56.4M | -11.33M | -10.14M | -9.04M |
Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 104.39M | 171.13M | 37.42M | 40.91M | 250.01M |
Operating Income | -51.68M | 27.38M | -73.62M | -50.84M | 122.01M |
Net Income | -43.6M | 36.74M | -71.2M | -46.41M | 132.33M |
Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 294.65M | 351.28M | 469.59M | 436.23M | 426.04M |
Total Liabilities | 118.43M | 114.96M | 128.71M | 100.81M | 95.73M |
Total Equity | 176.22M | 236.32M | 340.89M | 335.42M | 330.31M |
Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 354.76M | 261.58M | 193.86M | 159.36M | 351.28M |
Total Liabilities | 255.25M | 107.26M | 98.8M | 100.34M | 114.96M |
Total Equity | 99.51M | 154.32M | 95.06M | 59.02M | 236.32M |
Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | 101.68M | 77.92M | 58.77M | 27.19M | -781k |
Investing | -168.48M | -141.64M | -96.07M | -132.01M | -67.66M |
Financing | 33.19M | 33.65M | 112.86M | 113.43M | 113.44M |
Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | 48.67M | -96.72M | -53.53M | -12.51M | 77.92M |
Investing | -90.48M | 113M | 65.91M | -7.34M | -141.64M |
Financing | 80.99M | 3.16M | 612k | 1.11M | 33.65M |
Market Cap | 313.55M |
Price to Earnings Ratio | 2.37 |
Price to Sales Ratio | 1.25 |
Price to Cash Ratio | 4.56 |
Price to Book Ratio | 1.33 |
Dividend Yield | - |
Shares Outstanding | 54.63M |
Average Volume (1 week) | 315.17k |
Average Volume (1 Month) | 477.11k |
52 Week Change | -34.70% |
52 Week High | 11.72 |
52 Week Low | 5.19 |
Spread (Intraday) | 0.4 (6.67%) |
Company Name | Voyager Therapeutics Inc |
Address |
corporation trust center wilmington, delaware 19801 |
Website | https://www.voyagertherapeutics.com |
Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions